THANK YOU FOR YOUR INTEREST,
PRE-REGISTRATION IS CLOSED.

Onsite registration is available as space allows.
Please see registration staff in New Orleans.

FRIDAY, DECEMBER 6, 2013


CME Luncheon Symposium
12:15 PM - 4:30 PM


New Orleans Marriott | 3rd Floor
555 Canal Street, New Orleans, LA
Grand Ballroom - Acadia and Bissonet


PROGRAM AGENDA
12:15 PM Registration/Lunch
1:10 PM LLS Welcome
  Louis J. DeGennaro, PhD
Executive Vice President, Chief Mission Officer
1:15 PM Introduction
  Cheryl L. Willman, MD
1:20 PM Applying Next Generation Sequencing Technologies to Hematologic Malignancies –
The Next Era
  Elaine R. Mardis, PhD
1:50 PM Genomic Approaches to Target Aberrant Transcription in Leukemia
  Kimberly Stegmaier, MD
2:20 PM Therapeutic Strategies in Lymphoma From Functional and Structural Genomics
  Louis M. Staudt, MD, PhD
2:50 PM Functional Genomic Approaches for Delivery of Personalized, Targeted Therapies
  Jeffrey Tyner, PhD
3:20 PM Genomic Testing in Clinical Practice –
Privacy, Ethical and Legal Considerations
  Samuel Volchenboum, MD, PhD, MS
  Informed Consent for Cancer Research in the 21st Century: It’s Complicated
  Eric Kodish, MD
3:50 PM Panel Discussion and Q&A


FACULTY

Cheryl L. Willman, MD
The Maurice & Marguerite Liberman Distinguished Chair in Cancer Research
Professor of Pathology and Internal Medicine
Director & CEO
University of New Mexico Cancer Center
Albuquerque, New Mexico

Elaine R. Mardis, PhD
Professor of Genetics and Molecular Microbiology
Co-Director, The Genome Institute at Washington University
Washington University School of Medicine
St. Louis, MO

Kimberly Stegmaier, MD
Associate Professor of Pediatrics, Harvard Medical School
Dana-Farber Cancer Institute/Boston Children's Hospital
Boston, MA

Louis M. Staudt, MD, PhD
Director
Center for Cancer Genomics
National Cancer Institute
Bethesda, MD

Jeffrey W. Tyner, PhD
Assistant Professor
Oregon Health & Science University
Portland, OR

Samuel L. Volchenboum, MD, PhD, MS
Assistant Professor of Pediatrics
Director, Informatics Program
The University of Chicago Medicine
Comer Children’s Hospital
Chicago, IL

Eric Kodish, MD
F.J. O’Neill Professor and Chairman, Department of Bioethics
Director, Center for Ethics, Humanities and Spiritual Care
Cleveland Clinic
Cleveland, OH


TARGET AUDIENCE
This activity is designed for hematologists, oncologists, and other healthcare professionals who have an interest in the study and treatment of hematologic malignancies.


STATEMENT OF NEED
Genomic and other omics-based technologies offer great promise for improved diagnosis and treatment of hematologic malignancies. Within the past decade, the knowledge and tools derived from the completed sequencing of the human genome have transformed the diagnosis and classification of hematologic malignancies. Genomics have also vastly expanded our understanding of the behavior of transformed cells. In particular, the availability of the human genome sequence has allowed us to gain greater insight into how chromosomal changes and the activation of key cellular pathways influence malignant transformation.

Research using genomics allows us to identify important molecules that may be targeted for inhibition in order to block cancer progression. To maximize the benefit of targeted therapies, however, it is important to know the gene expression profile of the cancer cells, in order to effectively predict responses to a therapy. Knowledge of the gene expression profile of patients’ tumor cells would, thus, allow us to better tailor the treatment strategies to individual patients. Cancer researchers are currently working toward the goal making genomic profiling a routine part of patient care, aided by the rapid advances in genomic science and sequencing capabilities.

As omics technologies become increasingly more accessible in clinical medicine, new ethical, legal, and social issues may be presented. It is critical that researchers and clinicians treating patients with hematologic malignancies are well informed about both the potential applications of omics-based technologies to future research and disease management and the concomitant ethical, social, and legal issues that may be raised. This knowledge will help physicians to effectively implement these new technologies into their practice in order to maximize benefits to patients.


EDUCATION OBJECTIVES
After completing this activity, participants should be better able to:

  • Define the state of the art for genomic analyses for several hematologic malignancies
  • Describe how cancer genomics contributes to disease pathology
  • Discuss the therapeutic potential of using cancer genomics in diagnosis and treatment
  • Apply the information presented about using genomic information from clinical trials and best practices to better manage patients with hematologic malignancies
  • Describe key issues related to use of omics in data sharing via the Internet and privacy concerns

PHYSICIAN CONTINUING EDUCATION CREDIT

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Leukemia & Lymphoma Society, RMEI, LLC and Postgraduate Institute for Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


FEE INFORMATION
There is no fee for this educational activity. Per regulatory guidelines, the educational grants used to support this activity may only be used for medical professionals attending the activity. Participation by non-healthcare providers and/or guests is not permitted.


AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact us prior to the live event at (866) 992-9950, extension 338.


STATEMENT OF SUPPORT
This activity is jointly sponsored by The Leukemia & Lymphoma Society, RMEI, LLC and Postgraduate Institute for Medicine and supported by educational grants from Celgene Corporation and Millennium: The Takeda Oncology Company.




Send to a friend

Facebook  Twitter  YouTube


For information on leukemia, lymphoma or myeloma contact an LLS Information Specialist at (800) 955-4572 or infocenter@LLS.org. Or visit www.LLS.org.